

Surgical removal of rheumatoid nodules

Commissioning decision	The ICB will provide funding for the surgical removal of rheumatoid nodules for patients who meet the criteria defined within this policy. Funding approval for eligible patients must be sought from the ICB via the Prior Approval process prior to treatment.
------------------------	--

Policy Statement:

Requests for funding will only be approved where one of the following criteria are met:

- Significant pain and/or tenderness of nodules **OR**
- Complications such as infection and ulceration OR
- Pressure symptoms including nerve compression or pressure on an organ or tissue

OR

 Its size or position is causing severe functional impairment of activities of daily living**

** Significant functional impairment is defined by the ICB as:

- o Symptoms prevent the patient fulfilling vital work or educational responsibilities
- o Symptoms prevent the patient carrying out vital domestic or carer activities

Rationale:

Rheumatoid nodules are usually referred to an orthopaedic surgeon for excision, most commonly a hand surgeon or upper limb surgeon, depending on the site and after the patient has received counselling about the risk of recurrence.

Separate guidelines will apply for excision of rheumatoid nodules in the lung where a differential diagnosis of malignancy is considered.

Plain English Summary:

Rheumatoid nodules are bumps in the bones which are different to other types of lumps on joints called ganglia. Rheumatoid nodules tend to occur in patients with more severe forms of the disease rheumatoid arthritis (RA). They appear most commonly on the elbow, forearm, fingers and thumbs or other bony areas following an injury. They may be painful or may cause no pain at all and may vary in size. If they are removed by surgery, they may appear again after a time. They can be difficult to treat with medicines or injections into the joint area.

Surgery may be an option for people who have painful or large nodules which affect the ability to perform activities of daily living as outlined in this policy.





Evidence base:

Rheumatoid Nodules: Dermatologic clinics; Jul 2015; vol. 33 (no. 3); p. 361-371Tilstra, Jeremy S; Lienesch, Douglas W

For further information please contact <u>GLICB.IFR@nhs.net</u>

Date of publication	November 2018
Policy review date	May 2024

Policy sign off:

Reviewing Body	Date of review
Effective Clinical Commissioning Policy Group	October 2018
Quality and Governance Committee	

Version Control:

Version No	Type of Change	Date	Description of Change
0.01	New Policy	22/11/2018	n/a
0.02	Review date	18/05/2021	Evidence base updated;
	Evidence base		Review date agreed at 3
			years.